Announcements

1. “3D Printing of Mini Tablets for Pediatric Use”
by Julius Krause, Laura Müller, Dorota Sarwinska, Anne Seidlitz, Malgorzata Sznitowska and Werner Weitschies
Pharmaceuticals 2021, 14(2), 143; https://doi.org/10.3390/ph14020143
Available online: https://www.mdpi.com/1424-8247/14/2/143

2. “D-α-Tocopherol-Based Micelles for Successful Encapsulation of Retinoic Acid”
by Guendalina Zuccari, Sara Baldassari, Silvana Alfei, Barbara Marengo, Giulia Elda Valenti, Cinzia Domenicotti, Giorgia Ailuno, Carla Villa, Leonardo Marchitto and Gabriele Caviglioli
Pharmaceuticals 2021, 14(3), 212; https://doi.org/10.3390/ph14030212
Available online: https://www.mdpi.com/1424-8247/14/3/212

3. “In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN)”
by Cláudia Pina Costa, Sandra Barreiro, João Nuno Moreira, Renata Silva, Hugo Almeida, José Manuel Sousa Lobo and Ana Catarina Silva
Pharmaceuticals 2021, 14(8), 711; https://doi.org/10.3390/ph14080711
Available online: https://www.mdpi.com/1424-8247/14/8/711

4. “CD44-Targeted Carriers: The Role of Molecular Weight of Hyaluronic Acid in the Uptake of Hyaluronic Acid-Based Nanoparticles”
by Enrica Chiesa, Antonietta Greco, Federica Riva, Rossella Dorati, Bice Conti, Tiziana Modena and Ida Genta
Pharmaceuticals 2022, 15(1), 103; https://doi.org/10.3390/ph15010103
Available online: https://www.mdpi.com/1424-8247/15/1/103

5. “Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles”
by Lina Zhou, Sunitha Kodidela, Sandip Godse, Stacey Thomas-Gooch, Asit Kumar, Babatunde Raji, Kaining Zhi, Harry Kochat and Santosh Kumar
Pharmaceuticals 2022, 15(3), 358; https://doi.org/10.3390/ph15030358
Available online: https://www.mdpi.com/1424-8247/15/3/358

1. ”Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme”
by Michele Stella, Luca Falzone, Angela Caponnetto, Giuseppe Gattuso, Cristina Barbagallo, Rosalia Battaglia, Federica Mirabella, Giuseppe Broggi, Roberto Altieri, Francesco Certo et al.
Pharmaceuticals 2021, 14(7), 618; https://doi.org/10.3390/ph14070618
Available online: https://www.mdpi.com/1424-8247/14/7/618

2. “Lung Fibrosis after COVID-19: Treatment Prospects”
by Evgeny Bazdyrev, Polina Rusina, Maria Panova, Fedor Novikov, Ivan Grishagin and Vladimir Nebolsin
Pharmaceuticals 2021, 14(8), 807; https://doi.org/10.3390/ph14080807
Available online: https://www.mdpi.com/1424-8247/14/8/807

3. “Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences”
by Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, Anna Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio and Marco Scarselli
Pharmaceuticals 2021, 14(3), 238; https://doi.org/10.3390/ph14030238
Available online: https://www.mdpi.com/1424-8247/14/3/238

4. “Antiseizure Effects of Cannabidiol Leading to Increased Peroxisome Proliferator-Activated Receptor Gamma Levels in the Hippocampal CA3 Subfield of Epileptic Rats”
by Anna-Maria Costa, Fabiana Russo, Lara Senn, Davide Ibatici, Giuseppe Cannazza and Giuseppe Biagini
Pharmaceuticals 2022, 15(5), 495; https://doi.org/10.3390/ph15050495
Available online：https://www.mdpi.com/1424-8247/15/5/495

5. “N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review”
by Marta Guerini, Giorgia Condrò,  Valeria Friuli,  Lauretta Maggi and Paola Perugini
Pharmaceuticals 2022, 15(2), 217; https://doi.org/10.3390/ph15020217
Available online: https://www.mdpi.com/1424-8247/15/2/217

1. “Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease”
by Caitlin V. M. L. Jie, Valerie Treyer, Roger Schibli and Linjing Mu
Pharmaceuticals 2021, 14(2), 110; https://doi.org/10.3390/ph14020110
Available online: https://www.mdpi.com/1424-8247/14/2/110

2. “Alpha-Synuclein PET Tracer Development—An Overview about Current Efforts”
by Špela Korat, Natasha Shalina Rajani Bidesi, Federica Bonanno, Adriana Di Nanni, Anh Nguyên Nhât Hoàng, Kristina Herfert, Andreas Maurer, Umberto Maria Battisti, Gregory David Bowden, David Thonon et al.
Pharmaceuticals 2021, 14(9), 847; https://doi.org/10.3390/ph14090847
Available online: https://www.mdpi.com/1424-8247/14/9/847

3. “[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer”
by Ute Hennrich and Matthias Eder
Pharmaceuticals 2021, 14(8), 713; https://doi.org/10.3390/ph14080713
Available online: https://www.mdpi.com/1424-8247/14/8/713

4. “Development of ¹⁸F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging”
by Rocío García-Vázquez, Jesper Tranekjær Jørgensen, Klas Erik Bratteby, Vladimir Shalgunov, Lars Hvass, Matthias M. Herth, Andreas Kjær and Umberto Maria Battisti
Pharmaceuticals 2022, 15(2), 245; https://doi.org/10.3390/ph15020245
Available online: https://www.mdpi.com/1424-8247/15/2/245

5. “E-Cigarette Aerosol Deposition and Disposition of [¹¹C]Nicotine Using Positron Emission Tomography: A Comparison of Nicotine Uptake in Lungs and Brain Using Two Different Nicotine Formulations”
by Anders Wall, Sara Roslin, Beatrice Borg, Simon McDermott, Tanvir Walele, Thomas Nahde, Grant O’Connell, Joseph Thompson, Mark Lubberink and Gunnar Antoni
Pharmaceuticals 2022, 15(3), 367; https://doi.org/10.3390/ph15030367
Available online: https://www.mdpi.com/1424-8247/15/3/367

This conference organized by the British Pharmacological Society and International Union of Basic and Clinical Pharmacologists (IUPHAR) will be held in Glasgow, Scotland, from 2 July to 7 July 2023. The topic of the conference focuses on pharmacology and drug discovery, research, and development, and the conference will include six days of symposia, keynote lectures, workshops, and debates. Discover the latest in pharmacology research and developments across 10 content themes.

Pharmaceuticals (ISSN: 1424-8247) is a peer-reviewed, open access journal of medicinal chemistry and related drug sciences, published monthly online by MDPI. Pharmaceuticals will participate in this event as an exhibitor together with nine other MDPI journals, among which Pharmaceuticals, Journal of Personalized Medicine and Biomedicines will have journal representatives at our booth.

The following MDPI journals will be represented:

• Pharmaceuticals (leading journal);
• Biomedicines;
• JPM;
• JCM;
• Marine Drugs;
• Children;
• Current Oncology;
• BioMedInformatics;
• JoX;
• Rheumato.

If you are attending this conference, please feel free to start a conversation with us at our booth #A22. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://wcp2023.org/ or contact the Pharmaceuticals Editorial Office at pharmaceuticals@mdpi.com.

As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.

In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.

If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to newjournal-committee@mdpi.com.

MDPI is pleased to announce that we now display the co-authors’ email addresses in addition to the corresponding author’s email address on the webpage of published papers, protected by Captcha. For more information about this change, please visit the journal’s instructions for authors page. 

We believe this change will facilitate academic discussions and advance our cause of open science and research. The corresponding authors are responsible for communicating with their co-authors and indicating in our system (https://susy.mdpi.com/) if co-authors would prefer for their email addresses not to be displayed.

Conference: 143rd Annual Meeting of the Pharmaceutical Society of Japan
Date: 25–28 March 2023
Place: Sapporo, Japan

MDPI will be attending the 143rd Annual Meeting of the Pharmaceutical Society of Japan as the exhibitor. This meeting will be held at Hokkaido University, Sapporo, Japan, from 25 to 28 March 2023. The organizing committee comprises the Faculty of Pharmaceutical Sciences, Hokkaido University. The theme of the 143rd annual meeting is "PharmaScience: Integration for Breakthroughs". Through this meeting, we wish to contribute to the progress of research leading to the development of innovative drugs and therapies by bringing together researchers from various research fields.

The following MDPI journals will be represented:

• Biomedicines;
• JPM;
• Pharmaceutics;
• JCM;
• Pharmaceuticals.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://confit.atlas.jp/guide/event/pharm143/top.

On 9 February 2023, Clarivate, a global leader in providing trusted insights and analytics, added the Preprint Citation Index to the Web of Science platform, streamlining the research process by allowing researchers to locate and link to preprints alongside other trusted content in the database.

The Preprint Citation Index will act as a bridge to connect cutting-edge preprints with peer-reviewed journal articles published within the Web of Science Core Collection. Alerts can be easily set to monitor new research across several repositories and authors will also be able to include preprints on their Web of Science Research Profile to more accurately display their various research outputs.

As of its launch, the Preprint Citation Index will provide nearly two million preprints from various repositories, including MDPI’s own Preprints.org.

MDPI's Preprints Platform – Preprints.org

To advance Open Science and the fast dissemination of research, MDPI offers researchers a free multidisciplinary preprint platform. Preprints.org accepts submissions from all research areas and offers authors high visibility, permanent archiving, article-level Metrics and immediately citable content by assigning a Digital Object Identifier (DOI) to all preprints.

During submission to any MDPI journal, authors have the option to share their research as a preprint. After an initial screening, the manuscript is available online in 48 hours or less. Once online, preprints can be downloaded, shared, commented on, and cited, providing authors maximum visibility.

We invite you to join the ranks of the over 100k researchers using Preprints.org and share your research.

For more information, please visit Preprints.org.

We are pleased to announce the launch of a new initiative—the MDPI Special Issue Mentor Program.

This program will enable early career researchers (who must hold a Ph.D. in a related field) to experience editing a Special Issue in MDPI journals, under the mentorship of our experienced Editorial Board Members or other experienced scientists. The mentor program will provide an excellent opportunity for early career scientists to gain editorial experience, and to cultivate their ability to edit scientific research.

The mentee’s responsibilities include:

• Proposing a Special Issue title and assisting the mentor in preparing a summary (around 200–400 words) and 3–10 keywords describing the background, importance, and goal of the Issue;
• Writing a brief promotion plan for the Special Issue;
• Preparing a list of scholars who may be interested in the Issue and personally e-mailing invitations on behalf of Guest Editors;
• Writing an editorial for the online Special Issue together with the mentor.

The mentor’s responsibilities include:

• Conducting a final check before the Special Issue is published online;
• Performing editorial control of the Special Issue and quality control of the publications, both of which must be carried out in a timely manner;
• Providing suggestions to younger scholars if they have any doubts or concerns regarding submissions;
• Organizing video calls with young scholars and the Editorial Office regularly to discuss problems and improvement suggestions for the Special Issue;
• Making and submitting decisions regarding submissions with the assistance of mentees.

Certificates and awards:
After the Special Issue closes, the Editorial Office will provide official certificates for all the mentors and early career researchers.

If you are interested in this opportunity, please send your Special Issue proposal to the Editorial Office of a journal you choose, and we will discuss the process (i.e., mentor collaboration, Special Issue topic feasibility analysis, etc.) in further detail. The full list of MDPI journals is as follows: https://www.mdpi.com/about/journals.

In addition to the new Special Issue Mentor Program, we will continue to welcome all Special Issue proposals focusing on hot research topics.

MDPI has just become the first open access (OA) publisher to reach the milestone of one million articles published. That is one million articles freely available to all, to circulate and build upon! We are proud to share this special moment with the global scientific community.

This landmark has been reached thanks to the immeasurable support of more than 600,000 expert reviewers, 66,000 editorial board members and 6700 hard-working colleagues across MDPI’s global offices.

Within more than 25 years of publishing, our journals received 2.1 million manuscripts and generated 4.6 million peer review reports to get to one million papers published.

Reaching the milestone of one million articles published reinforces our mission to remove any existing barriers and to make scientific research accessible to all. Since its inception, MDPI’s goal has been to create reliable processes to make science open. This is a path towards facilitating the dissemination of novel insights in scientific communities.

Regular feedback from authors and reviewers shows that our service is greatly appreciated and needed. At the same time, the feedback helps us identify areas for further improvement.

As it stands, a significant share of published research findings remain closed access. More than half of the content published with the most well-known legacy publishers stays behind a paywall, and that is not including articles published in hybrid OA journals, or made available months or years after publication.

A new policy announced by the US administration in August 2022 requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. While the new policy does not mandate articles be published under an open access license, it is aligned with the open access movement in removing all barriers to research. Similarly, some of the most advanced research institutions in the world intend to have all funded research articles published in open access by 2025.

MDPI is proud to be the leading agent of the transition to open access.

"Thanks a Million" to all the contributors!